EXCLI journal|2026|Bernardo M et al.
PMID: 41768861
15038 studies
We report a case of life-threatening malnutrition and liver injury in a post-Roux-en-Y gastric bypass patient after initiation of semaglutide, who subsequently developed profound micronutrient deficiencies and acute liver injury requiring ICU care, p…
BACKGROUND: In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between o…
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a novel pharmacotherapeutic option for pediatric type 2 diabetes (T2D); however, little is known about their current use. This study evaluated trends in GLP-1RA dispensing in youth w…
BACKGROUND: Orforglipron is a novel non-peptide (GLP-1) receptor agonist designed for daily oral administration without food or water restrictions. This study aimed to compare the efficacy and safety of orforglipron with oral semaglutide in individua…
BACKGROUND: Alzheimer's disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping biological mechanisms, and diabetes increases the risk of developing AD. Treatments that modify the course of diabetes, such as metformin and semaglutide, have…
BACKGROUND: Despite the clinical efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss, real-world persistence remains substantially lower than seen in clinical trials. Since 2021, GLP-1RA shortages and changes in product a…
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists, including a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist, have expanded treatment options for overweight and obesity. However, real-world data within Medicaid pop…
This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal muscle weakness and creatine kinase elevation over…
INTRODUCTION: Type 2 diabetes (T2D) is a critical public health crisis in Pakistan, which currently holds the highest age-standardised prevalence globally. While semaglutide significantly improves glycemic control and weight, high costs limit access…
BACKGROUND: Obesity affects over 40% of US adults, with severe obesity on the rise. Despite recognition of obesity as a chronic disease, it remains underdiagnosed and undertreated. Access to evidence-based obesity treatment is limited, leading to inc…
INTRODUCTION: Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat-free mass and fat mass losses) and mass-independent adaptations in EE (e.g., hormones). Glucagon-like peptide-1 receptor agonists (GLP…
OBJECTIVE: To evaluate the comparative effectiveness of dulaglutide or semaglutide versus tirzepatide on cardiovascular outcomes in adults with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). RESEARCH DESIGN AND METHODS: Two…
OBJECTIVE: To examine the effects of semaglutide on insulin sensitivity, insulin resistance, and β-cell function and explore whether these changes were mediated by weight loss in overweight or obese individuals with schizophrenia and prediabetes rece…
BACKGROUND AND STUDY AIMS: Comparison of the therapeutic effects of endoscopic botulinum toxin (BTX) injection and semaglutide (SME) injection in treatment of patients with obesity and weight regain after laparoscopic sleeve gastrectomy (LSG). PATIEN…
GLP-1 receptor (GLP-1R) agonists decrease blood glucose and body weight and reduce rates of cardiovascular and renal disease. Although GLP-1R activation lowers blood pressure (BP), the underlying mechanisms remain incompletely understood and have bee…
The global rise in obesity and depression, two highly prevalent and often comorbid disorders has intensified interest in the gut–brain axis as a shared biological link. Mounting evidence indicates that the gut microbiota profoundly influences both me…
BACKGROUND: Obesity has been proposed as a risk factor for the development of rheumatoid arthritis (RA). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for weight reduction and glycemic control and have been shown to…
Euglycemic ketoacidosis is a rare but increasingly recognized adverse effect related to the use of glucagon-like peptide-1 (GLP-1) receptor agonists. Reduced oral intake in combination with gastrointestinal side effects can trigger a starvation state…